Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas

N. Shoushtari, Alexander; K. Chatila, Walid; Arora, Arshi; Sánchez-Vega, Francisco; S. Kantheti, Havish; A. Rojas Zamalloa, Jorge; Krieger, Penina; K. Callahan, Margaret; Betof Warner, Allison; A. Postow, Michael; Momtaz, Parisa; Nair, Suresh; E. Ariyan, Charlotte; A. Barker, Christopher; S. Brady, Mary; G. Coit, Daniel; Rosen, Neal; B. Chapman, Paul; J. Busam, Klaus; B. Solit, David; S. Panageas, Katherine; D. Wolchok, Jedd; Schultz, Nikolaus

doi:10.1158/1078-0432.ccr-20-4189

Public

Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas

Published in Clinical Cancer Research • Jan 28, 2021

Authors:

Alexander N. Shoushtari

Walid K. Chatila

Arshi Arora

Abstract

Abstract Purpose: Cutaneous and unknown primary melanomas frequently harbor alterations that activate the MAPK pathway. Whether MAPK driver detection beyond BRAF V600 is clinically relevant in the checkpoint inhibitor era is unknown. Experimental Design: Patients with melanoma were prospectively off...

Subject

Nivolumab

Ipilimumab

Neuroblastoma RAS viral oncogene homolog

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!